Advanced Enzyme Technologies Limited (ADVENZYMES.NS)
- Previous Close
386.30 - Open
386.95 - Bid 390.05 x --
- Ask 390.20 x --
- Day's Range
385.20 - 392.70 - 52 Week Range
255.00 - 425.15 - Volume
72,118 - Avg. Volume
284,965 - Market Cap (intraday)
43.662B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
31.80 - EPS (TTM)
12.28 - Earnings Date May 11, 2024 - May 15, 2024
- Forward Dividend & Yield 6.00 (1.55%)
- Ex-Dividend Date Aug 4, 2023
- 1y Target Est
333.00
Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
www.advancedenzymes.com338
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: ADVENZYMES.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADVENZYMES.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADVENZYMES.NS
Valuation Measures
Market Cap
43.20B
Enterprise Value
38.87B
Trailing P/E
31.48
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.14
Price/Book (mrq)
3.46
Enterprise Value/Revenue
6.43
Enterprise Value/EBITDA
17.09
Financial Highlights
Profitability and Income Statement
Profit Margin
22.67%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6.05B
Net Income Avi to Common (ttm)
1.37B
Diluted EPS (ttm)
12.28
Balance Sheet and Cash Flow
Total Cash (mrq)
4.68B
Total Debt/Equity (mrq)
2.99%
Levered Free Cash Flow (ttm)
--
Research Analysis: ADVENZYMES.NS
Company Insights: ADVENZYMES.NS
ADVENZYMES.NS does not have Company Insights